Indaptus Therapeutics, Inc.

Indaptus Therapeutics, Inc. entered into a Stock Purchase Agreement on June 17, 2026, to sell 20,000,000 shares of its common stock at $0.60 per share in a private placement. This transaction generated approximately $12,000,000 in gross proceeds for the company. The shares were sold to certain non-U.S. accredited investors, and the company is required to file a registration statement for the resale of these shares within 90 days.

Indaptus Therapeutics announced the resignations of two directors, Mr. David E. Lazar and Mr. Avraham Ben-Tzvi, from all directorship positions, effective June 5, 2026. Additionally, Mr. Walt A. Linscott, Esq. resigned as Chief Operating Officer, effective June 1, 2026, but will transition to a consulting role for the Company. The Company stated that these resignations were not due to any disagreements regarding its operations, policies, or practices.

Indaptus Therapeutics reported a net loss of $2.54 million for the first quarter of 2026, an improvement from a $4.53 million loss in the prior year. However, the company's cash and cash equivalents significantly declined to $1.50 million, leading to substantial doubt about its ability to continue as a going concern. Indaptus is actively exploring strategic transactions, including investments or acquisitions, to create future growth opportunities and secure additional capital.

Indaptus Therapeutics reported Q1 2026 financial results, showing a reduced net loss of $2.5 million compared to $4.5 million in Q1 2025, driven by decreased R&D and G&A expenses. However, the company's cash and cash equivalents significantly declined to $1.5 million from $8.5 million at the end of 2025, with net cash used in operating activities increasing to $7.0 million. Following executive management changes, the company is undergoing a strategic review of its development programs and acknowledges the critical need to raise additional capital.

Indaptus Therapeutics reported a net loss of $2.5 million, or $0.23 per share, for the first quarter ended March 31, 2026, an improvement from a $4.5 million net loss in the prior year. The company saw reduced R&D and G&A expenses. However, cash and cash equivalents significantly declined to $1.5 million, and the company stated it needs to raise additional capital. Indaptus is also undergoing an executive management transition and a strategic review of its development programs and resource allocation.

Indaptus Therapeutics, Inc. announced the appointment of Mr. Tim Ruan and Dr. Johnny Fox Arrowsmith as independent directors to its Board, effective April 22, 2026. Mr. Ruan, 40, brings significant experience as CFO of Ocumension Therapeutics and from senior roles at Goldman Sachs and Morgan Stanley. This filing is an amendment to clarify that Dr. Arrowsmith's legal name is Johnny Fox Arrowsmith, though he uses Yi Zhang professionally.

Indaptus Therapeutics, Inc. has entered into an indemnification agreement with its officers and directors. This agreement aims to protect them from expenses and liabilities incurred while serving the company, aligning with Delaware General Corporation Law. The company's bylaws already provide for such indemnification, and this agreement further formalizes the commitment to induce continued service.